U.S. Online Retail and Ecommerce Stock News

In late February 2026, Whirlpool completed roughly US$475 million of follow-on common equity issuance and about US$1.58 billion of preferred and depositary share offerings to repay debt and fund corporate initiatives, triggering sharp criticism from major shareholder Appaloosa over dilution and capital allocation. Appaloosa’s public rebuke of Whirlpool’s board and management, including calls to invite potential partners or buyers, injects governance and control questions directly into the...

Shoals Technologies Group (SHLS) is back in focus after reporting record quarterly revenue and backlog, issuing 2026 guidance, and announcing an ON.energy partnership targeting power systems for AI data centers and battery storage. See our latest analysis for Shoals Technologies Group. Despite record revenue and a large backlog, Shoals’ recent earnings miss and new guidance coincided with a sharp reset in sentiment. A 7 day share price return of a 44.1% decline and a 1 year total shareholder...

If you are trying to figure out whether USA Rare Earth is attractively priced or already baking in a lot of optimism, you are in the right place. The stock last closed at US$18.90, with returns of 9.7% over the past week, a 14.4% decline over the last 30 days, and gains of 33.6% year to date and 69.8% over the past year. That performance will catch the eye of anyone tracking shifts in risk and reward. Recent attention on USA Rare Earth has focused on its role in rare earth supply chains and...

Celsius Holdings (NasdaqCM:CELH) reported record full year revenue in 2025. Results were driven by the acquisitions and integration of Alani Nu and Rockstar Energy. The company further integrated into the PepsiCo system and expanded internationally. Celsius launched a new brand studio and a Fizz Free product line during 2025. Celsius Holdings operates in the energy drink category, a segment that continues to attract strong consumer attention as shoppers look for functional beverages and...

In its recently filed 2025 10-K, First Bancorp outlined past actions to strengthen liquidity and capital, including reinvesting in higher-yielding securities and maintaining a diversified deposit base, while reporting a 14.4% increase in shareholders’ equity and a CET1 ratio of 14.10%. The filing also underscored a business mix shift toward more variable-rate loans and relatively weak revenue growth and net interest margin versus peers, sharpening investor focus on how the bank manages...

If you are wondering whether Uber Technologies is priced attractively right now, you are not alone. A closer look at its current valuation can help you decide how it fits into your portfolio. Uber shares last closed at US$75.42, with returns of 2.1% over the past 7 days, a 5.5% decline over 30 days, a 9.0% decline year to date, a 0.8% decline over 1 year, a 118.2% gain over 3 years and a 35.8% gain over 5 years. Recent headlines around Uber have continued to focus on its role as a major...

Sharplink (NasdaqCM:SBET) has appointed digital assets specialist Steven Ehrlich as Head of Research and Communications. Ehrlich brings experience from prior roles at Forbes and Unchained, where he focused on digital asset journalism and research. The appointment marks a change in Sharplink’s leadership team aimed at strengthening its research and communication function. For investors, this move sits at the intersection of media, data, and digital assets, an area that continues to attract...

Clover Health Investments FY 2025 Earnings Snapshot Clover Health Investments (CLOV) has wrapped up FY 2025 with Q4 revenue of US$487.7 million and a basic EPS loss of US$0.10, alongside a trailing 12 month revenue figure of about US$1.9 billion and a basic EPS loss of US$0.17 that keeps the company in loss making territory. Over the past few quarters, the company has seen quarterly revenue move from US$462.3 million in Q1 2025 to US$496.7 million in Q3 2025 before ending the year at US$487.7...

Autodesk (ADSK) has wrapped up FY 2026 with Q4 revenue of US$1.96b and basic EPS of US$1.49, alongside trailing twelve month revenue of US$7.21b and EPS of US$5.28, setting a clear reference point for how the business is currently performing. Over recent periods, the company has seen revenue move from US$6.13b on a trailing basis in FY 2025 to US$7.21b in FY 2026, while trailing EPS shifted from US$5.17 to US$5.28. This gives investors a clearer view of how top line scale and per share...

If you are wondering whether Grab Holdings is attractively priced at its current level, this article will walk through what the latest data suggests about its valuation. The stock most recently closed at US$4.22, with returns of 3.7% decline over 7 days, 6.8% decline over 30 days, 16.9% decline year to date, 13.0% decline over 1 year, 28.7% over 3 years and 63.4% decline over 5 years, which may prompt questions about how the market is reassessing its potential and risks. Recent coverage...

Why Quest Diagnostics is on investors’ radar today Quest Diagnostics (DGX) is drawing attention after recent share price moves, with the stock last closing at $211.91 and showing double digit total returns over the past year and past 3 months. See our latest analysis for Quest Diagnostics. The recent share price strength, including a 15.96% 1 month share price return and 21.93% year to date share price return, sits alongside a 1 year total shareholder return of 24.84%. This points to momentum...

In February 2026, State Street Investment Management launched five actively managed State Street MyIncome target-maturity high-yield corporate bond ETFs maturing between 2027 and 2031, while State Street Corporation declared cash dividends on its common and multiple preferred stock series payable in March and April 2026. This combination of new income-focused ETFs and ongoing preferred and common dividends highlights State Street’s effort to broaden fee-based products while continuing cash...

With no single headline event driving today’s move, Credit Acceptance (CACC) is drawing attention as investors weigh its recent share performance and current valuation signals in relation to the company’s latest reported fundamentals. See our latest analysis for Credit Acceptance. At a share price of $473.18, Credit Acceptance has seen a 9.17% 1 month share price return and a 4.24% year to date share price return, while its 1 year total shareholder return decline of 3.90% and 5 year total...

Eastman Chemical (NYSE:EMN) has completed a major fixed-income offering of unsecured notes with a fixed coupon and long maturity. The new issuance adjusts the company’s capital structure and adds a long term funding source to its balance sheet. This move has implications for liquidity, interest costs, and how Eastman approaches future borrowing and investment decisions. For investors watching NYSE:EMN, this bond deal comes after a mixed share price track record, with the stock at $75.51 and...

In recent months, e.l.f. Beauty has accelerated customer‑driven product launches via TikTok Live, expanded its hit Glow Reviver lip balm line with a limited‑edition dill pickle flavor, raised its fiscal 2026 revenue guidance on stronger‑than‑expected Rhode performance, and drawn both a fiduciary‑duty investigation and shifting short‑interest levels. Taken together, these developments highlight how e.l.f. is leaning on rapid innovation, social‑media engagement, and the Rhode acquisition...

Palomar Holdings (PLMR) recently filed a shelf registration for up to US$125.05 million in common stock, covering 1,035,613 shares. This filing gives the insurer flexibility to issue equity for future ESOP related initiatives. See our latest analysis for Palomar Holdings. Against this backdrop, Palomar’s 1 day share price return of 1.53% and recent 30 day gain of 3.35% contrast with a softer year to date share price return of 6.15% and a 1 year total shareholder return of 3.85%. At the same...

Incyte (INCY) is back in focus after Eli Lilly and Incyte received a positive opinion from the European Medicines Agency for extending Olumiant to adolescents with severe alopecia areata, marking a new regulatory milestone for the partnership. See our latest analysis for Incyte. While the latest EMA opinion has put Incyte back in the headlines, the share price has been relatively steady in the short term, with recent 1 day and 30 day share price returns close to flat. However, the 1 year...

Agilent Technologies (NYSE:A) received FDA approval for its PD-L1 IHC 22C3 pharmDx as the only authorized companion diagnostic for certain ovarian and related cancers treated with KEYTRUDA. The approval covers use of the assay to help identify patients who may be eligible for KEYTRUDA based on PD-L1 expression. The decision expands the clinical indications for PD-L1 IHC 22C3 pharmDx within Agilent's broader oncology diagnostics portfolio. For investors, this news sits at the intersection of...

Earlier this week, Teradata announced it had entered into a settlement agreement with SAP, under which SAP will pay US$480 million to resolve all past and pending litigation related to alleged trade secret misappropriation, leaving Teradata with an expected net cash benefit of about US$355 million to US$362 million before taxes. This settlement not only removes a major legal uncertainty but also gives Teradata additional financial flexibility at a time when its cloud ARR grew 15% and it...

Diebold Nixdorf (NYSE:DBD) has named Jeffrey Sesplankis as its principal accounting officer. Sesplankis succeeds Thomas S. Timko in this key finance and reporting role. Diebold Nixdorf, known for its ATM, payments and retail technology solutions, sits at the intersection of banking infrastructure and physical commerce. For investors, changes in senior finance roles can matter as much as product announcements, because they speak to how the company manages its books, oversees internal...

NovoCure (NasdaqGS:NVCR) received FDA approval for Optune Pax in locally advanced pancreatic cancer and has started commercial launch. The approval extends the company’s Tumor Treating Fields technology beyond its historic focus in glioblastoma into a new oncology market. NovoCure also announced a new CEO and a reorganization of its clinical team alongside the launch. NovoCure now trades around $13.67, with the stock up 20.3% over the past week and 8.7% over the past month, while longer...

Teladoc Health (TDOC) is back in focus after reporting fourth quarter and full year 2025 results, updating its 2026 outlook, and adding experienced finance executive Michael S. Smith to its board. See our latest analysis for Teladoc Health. Teladoc Health’s recent earnings update, 2026 guidance and board appointment come against a weak backdrop, with a 7 day share price return of 10.97% contrasting with a 30 day share price return of 8.36% and a 1 year total shareholder return decline of...

If you are wondering whether McGrath RentCorp at around US$110.67 is offering good value today, you are not alone. This article is built to help you weigh up what that price really represents. The stock is up 5.2% year to date. However, it has seen a 1.9% decline over the last week, a 5.7% decline over the last month and a 7.7% decline over the last year, which can change how the market is viewing its potential and risk. Recent coverage has focused on McGrath RentCorp's position in equipment...

In late February 2026, Synthekine announced a collaboration and supply agreement with Merck to test STK-012 alongside Keytruda and chemotherapy in the ongoing global Phase 2 SYNERGY-101 trial for first-line, PD-L1 negative nonsquamous non-small cell lung cancer. This agreement underlines Merck’s push to extend Keytruda’s reach in difficult-to-treat lung cancer while sharing development risk and keeping full rights to its own therapy. We’ll now examine how Merck’s expanded Keytruda...